SHARE
COPY LINK

COVID-19

EU approves use of Pfizer-BioNTech vaccine in children 12 and over in Europe

The European Commission authorised the use of the Pfizer-BioNTech vaccine in 12- to 15-year-olds on Friday, following the European Medicines Agency's approval of administering the jabs to adolescents earlier in the day.

EU approves use of Pfizer-BioNTech vaccine in children 12 and over in Europe
A nurse prepares a syringe with saline solution before it is diluted with the Pfizer/BioNTech vaccine at the Evonik vaccination in Hanau, western Germany (Photo by THOMAS LOHNES / AFP)

This vaccine is already approved for people aged 16 and over in the EU.

Earlier this month, US regulators authorised the vaccine for children in the 12-to-15 age group, and it is now widely available.

The European Medicines Agency said that two doses of the vaccine would be needed in adolescents and should be given at least three weeks apart, which is the same guidance as for adult use.

Individual EU states would be able to decide whether or not they wanted to offer the vaccine to the 12 to 15-year-olds.

READ ALSO: Vaccines to be made available to children 12 and over in Germany starting June

Germany said on Thursday that it would start giving the vaccine to children from 12 to 15 from June 7th, which is when vaccine prioritisation for all adults is set to end in Germany.

READ ALSO: Covid jabs for children in Germany will be an ‘individual decision’, says Health Minister

Italy has also said it would extend its vaccination campaign to the over-12s, with approval from Italy’s regulator expected by Monday.

READ ALSO: Italy to open Covid jab appointments to all over-16s from June 3rd

And Austrian capital Vienna was waiting for the EMA approval before opening up Covid-19 vaccination registrations to parents of 12- to 15-year-olds.

In Switzerland, meanwhile, children may be able to get vaccinated at the age of 10, even without their parents’ approval.

The EMA approval may help reassure parents when children go back to face-to-face teaching, but the issue is not without controversy.

A few figures in the medical community have said there is not yet enough evidence to support vaccines and their potential side effects in younger people, while others believe older and vulnerable people in less wealthy countries should be prioritised over children.

Member comments

Log in here to leave a comment.
Become a Member to leave a comment.

COVID-19

Norway unlikely to offer fourth Covid vaccine dose to under 45s 

Those under 45 with no underlying conditions probably won’t be offered a fourth Covid vaccine dose this autumn, the Norwegian Institute of Public Health (NIPH) said Friday. 

Norway unlikely to offer fourth Covid vaccine dose to under 45s 

Health authorities are unlikely to offer under 45s a fourth Covid jab this autumn, broadcaster TV2 writes. 

“As it looks now, no more doses will be recommended for healthy people under the age of 45, but we are continuously assessing this based on the knowledge we have about the epidemic and the vaccine,” Preben Aavitsland, Chief Physician at the Norwegian Institute of Public Health (NIPH), told TV2. 

Newswire NTB were informed on Wednesday that health chiefs would make an official recommendation for the coming autumn and winter towards the end of summer. 

In a letter sent to municipalities earlier this month, the NIPH wrote that the most likely outcome was that local authorities would be asked to other a refresher dose to over 65s and those in vulnerable groups.

Aavitsland told TV2 that in the long run, it was possible the oldest would be offered an annual vaccine. However, this would depend on how long the pandemic endured and the spread of new variants, the chief physician, added. 

SHOW COMMENTS